Table 3.
Clinical relevance of tumor-associated Bregs.
| Reference | Breg Types | Cancer Type | Patient Number | Significant Correlation with Clinicopathological Features | Prognostic Significance |
|---|---|---|---|---|---|
| (48) | Circulating Bregs | HCC | 74 | Tumor UICC stages, tumor multiplicity and venous infiltration | —— |
| (36) | Circulating Bregs | Cervical cancer | 70 | FIGO stages, lymph node metastasis, tumor differentiation, HPV infection and tumor metastasis | —— |
| (39) | Tumoral Bregs | HCC | 51 | TNM stage, microvascular invasion and early recurrence | Negatively correlated with DFS and OS of patients who underwent curative surgical resection |
| (46) | Tumoral Bregs | TSCC | 46 | Correlated with clinical stage, local recurrence, and regional recurrence | Negatively associated with OS of TSCC patients |
| (49) | Bregs in PB and BM | AML | 46 | —— | An increased Breg percentage indicated a shorter OS for older patients or patients with high WBC levels. |
| (50) | Tumoral Bregs | GC | 30 | —— | Percentage of Bregs in tumor tissues was an independent prognostic indicator of GC patient survival. |
| (40) | Tumor Bregs | HCC | 43 | —— | Frequencies of PD-1hi Bregs in tumor tissues were significantly correlated with disease progression in patients. |
Breg, regulatory B cell; HCC, hepatocellular carcinoma; UICC, Union for International Cancer Control; FIGO, International Federation of Gynecology and Obstetrics; HPV, human papillomavirus; DFS, disease-free survival; OS, overall survival; TSCC, tongue squamous cell carcinoma; AML, acute myeloid leukemia; WBC, white blood cell; GC, gastric cancer; PB, peripheral blood; BM, bone marrow.